Tuberculosis Therapeutics Market, By Therapy Type (First-line Anti-TB Drugs (Isoniazid, Rifampicin, Others (Ethambutol, Pyrazinamide, etc.)), Second-line Anti-TB Drugs (Bedaquiline, Moxifloxacin, Others (Pretomanid, etc.)), Other Combination Drug Therapy/Late Phase Drugs, and Drug-Resistant TB Treatments (MDR-TB, XDR-TB)), By Disease Type (Latent TB, Active TB, Multi-Drug Resistant TB (MDR-TB), and Extensively Drug-Resistant TB (XDR-TB)), By Route of Administration (Oral and Parenteral (Injectables)), By Dosage Form (Tablets, Capsules, and Others (Injections)), By Age Group (Adult, Pediatric, and Geriatric), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), By End User Hospitals (Specialty clinics, Ambulatory Surgical Centers, Academic and Research Institutes, Homecare Settings, and Other Healthcare Facilities), By Geography (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa) - Growth Trends and Forecasts (2025-2032)